EPYSQLI

GrowthmAb

eculizumab-aagh

Samsung Bioepis
BLASOLUTIONINJECTION
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
30/100

Mechanism of Action

Complement Inhibitors

Pharmacologic Class:

Complement Inhibitor

Indications (2)

generalized myasthenia gravis (gMG) in adult patientshemolysis
Company
Samsung Bioepis
Samsung Bioepis
Korea - Incheon
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers